EMA Authorised: Tezspire (tezepelumab) — AstraZeneca AB

View source ↗

Summary

Authorised status for Tezspire (tezepelumab) by AstraZeneca AB for asthma and sinusitis in the EMA, indicating market authorisation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Rhinosinusitis with Without Nasal Polyps

Drugs mentioned

• Tezspire (tezepelumab)

Snippet

Status: Authorised. Therapeutic area: Asthma;Sinusitis. MAH: AstraZeneca AB. Decision date: 11/06/2026